Rx IP Update - April 2018

by Smart & Biggar
Contact

Smart & Biggar

IN THIS ISSUE:

Standing Committee on Health proposes National Pharmacare program, modifications to prescription and generic drug pricing

CADTH releases 2018-2021 Strategic Plan

Apotex fails to establish it would have obtained non-infringing perindopril from foreign third-party suppliers; original $61+ million profits award stands

Comparing Patent Term Extension Regimes Between Canada (CSPs) and the EU (SPCs) 

First CSPs issue, application fee increased on April 1

Supreme Court of Canada leave applications

HEALTH CANADA NEWS

Consultation on draft guidance governing public release of clinical information contained in drug submissions and medical device applications

Health Canada reports on public feedback from consultations on the proposed approach to regulation of cannabis

Health Canada intends to propose post-market amendments to the Medical Devices Regulations

 COURT DECISIONS

Apotex not entitled to reopen trial on esomeprazole (NEXIUM) patent validity

Two procedural decisions relating to HERCEPTIN under the amended PMNOC Regulations: confidentiality rules cannot be varied until action commenced; motion to dismiss may be brought prior to completion of examinations for discovery

Ontario Court of Appeal dismisses summary judgment appeal in section 8 case

New court proceedings

Standing Committee on Health proposes National Pharmacare program, modifications to prescription and generic drug pricing

By Abigail Smith

While common among member countries of the Organisation for Economic Co-operation and Development (OECD), Canada does not have a national pharmacare program, i.e. a single system of public insurance coverage for prescription drugs. On April 19, 2018, the Standing Committee on Health (Committee) released Pharmacare Now: Prescription Medicine Coverage for All Canadians, a report advocating the establishment of a national pharmacare program – specifically, a single payer universal publicly funded prescription drug coverage program for all Canadians, as an insured service under the Canada Health Act.

Read more >>

CADTH releases 2018-2021 Strategic Plan

By Andrew Mandlsohn

On April 16, 2018, the Canadian Agency for Drugs and Technologies in Health (CADTH) announced the release of its strategic plan for 2018-2021 entitled “Transforming How We Manage Health Technologies in Support of Better Health, Better Patient Experience, and Better Value”, and a brief summary overview of the plan. The CADTH, a health technology assessment agency, plans to transition to a health technology management agency by “[c]losing the gap between evidence, policy, and practice”, “[a]dopting a life-cycle approach to health technology assessment”, and “[a]nticipating health system and technology trends, and develop[ing] agile management strategies.”

Apotex fails to establish it would have obtained non-infringing perindopril from foreign third-party suppliers; original $61+ million profits award stands

By Urszula Wojtyra

Servier and its related company ADIR were successful in another chapter of patent litigation relating to perindopril (Servier’s COVERSYL): the Federal Court again dismissed Apotex’s non-infringing alternative defence, finding that Apotex would not have called on foreign third parties to manufacture perindopril to supply Apotex affiliates in the UK and Australia. The Court thereby re-affirmed its original judgment that Apotex Inc. and Apotex Pharmachem Inc. (collectively Apotex) must pay all their profits attributable to infringement of ADIR’s patent: ADIR v Apotex Inc, 2018 FC 346.

Read more >>

Comparing Patent Term Extension Regimes Between Canada (CSPs) and the EU (SPCs)

By Nancy Pei

Amendments to the Patent Act and enactment of the Certificate of Supplementary Protection Regulations flowing from the Canada-European Union (EU) Comprehensive Economic and Trade Agreement (CETA, see our article here) introduced a new framework in Canada for the issuance of Certificates of Supplementary Protection (CSPs). CSPs provide an additional patent-like protection term, and are intended to partly compensate the innovator for the time required for research and obtaining regulatory approval in Canada. CSPs are similar to the European system of Supplementary Protection Certificates (SPCs), with a number of key differences, including a shorter capped term of 2 years, as compared to 5 years in the EU. Key aspects of the two regimes are compared in the chart below.

A special thank you to Daniel Wise, partner, Carpmaels & Ransford, for contributing the SPC details.

View Chart >>

First CSPs issue, application fee increased on April 1

By Katie Lee

Health Canada has issued the first Certificates of Supplementary Protection (CSPs) against the following approvals: neisseria meningitidis grp B recombinant lipoprotein 2086 subfamily A/neisseria meningitidis grp B recombinant lipoprotein 2086 subfamily B (Pfizer’s TRUMENBA), letermovir (Merck’s PREVYMIS), and guselkumab (TREMFYA)(see: Register of Certificates of Supplementary Protection). In addition, the CSP application fee as of April 1, 2018 is $9,192.

Supreme Court of Canada leave applications

By Katie Lee

Teva seeks leave in levofloxacin damages assessment.
As previously reported, the Federal Court of Appeal (FCA) dismissed Teva’s appeal on the quantification of damages from infringement of Janssen’s patent for levofloxacin (LEVAQUIN). The FCA rejected Teva’s arguments, finding that the Federal Court did not err in constructing the hypothetical world, and that the Federal Court’s factual findings were open to it on the evidence. On March 26, 2018, Teva applied to the Supreme Court of Canada for leave to appeal (docket no. 38033).

Supreme Court denies leave regarding natural health product licence.
On April 12, 2018, the Supreme Court of Canada dismissed The Winning Combination’s leave to appeal (docket no. 37697). The Federal Court of Appeal decision had set aside the order of mandamus compelling the Minister of Health to grant a licence to The Winning Combination for its natural health product, RESOLVE (as previously reported).

Health Canada News

Consultation on draft guidance governing public release of clinical information contained in drug submissions and medical device applications

By Brandon Heard

As previously reported, on December 9, 2017, Heath Canada released proposed amendments to the Food and Drug Regulations and Medical Devices Regulations providing for the public release of clinical information contained in drug submissions and medical device applications. On April 10, 2018, Health Canada published a draft guidance document addressing implementation of the proposed amended regulations. According to the guidance:

  • Implementation will occur in 4 phases to take place over 4 years. In the first phase, Health Canada plans to proactively publish clinical information contained in any (i) new drug submission (NDS) for a new active substance, (ii) supplemental new drug submission (SNDS) containing confirmatory trials, or (iii) application to switch an authorized medicinal ingredient to non-prescription status. By year 4, this will expand to clinical information in any NDS, SNDS, abbreviated new drug submission (ANDS), or supplemental abbreviated new drug submission (SANDS) as well as any Class III or IV medical device application.
  • Upon issuance of a negative regulatory decision, the publication process will be delayed 30 days for the manufacturer to seek reconsideration or an appeal. Publication will be initiated upon completion of any reconsideration or appeal.
  • The manufacturer will be notified by email of the list of documents that will be publically released and will have 20 days to propose redactions and de-identify the data. Data anonymization must be explained in a separate “Anonymization Report”.
  • Redactions may be proposed for certain categories of clinical information that remain confidential business information (previously reported).
  • Clinical information from past submissions will be available upon request through Health Canada’s clinical information portal.

Health Canada is seeking stakeholder comments on the draft guidance, which may be submitted until June 25, 2018.

Health Canada reports on public feedback from consultations on the proposed approach to regulation of cannabis

By Andrew Mandlsohn

Bill C-45, An Act respecting cannabis and to amend the Controlled Drugs and Substances Act, the Criminal Code and other Acts (“Cannabis Act”) is currently before the Senate with a vote expected no later than June 7, 2018 (see Introduction of the Cannabis Act: Questions and Answers). The Government intends to publish final regulations as soon as possible following Royal Assent of the Cannabis Act. Rather than pre-publishing draft regulations, the Government released regulatory proposals by way of a consultation paper (previously reported). On March 19, 2018, Health Canada announced the release of its report entitled “Proposed Approach to the Regulation of Cannabis: Summary of Comments Received During the Public Consultation”. The report provides a summary of comments received on the consultation paper, including on matters such as licences, permits and authorizations, security clearances, a national Cannabis Tracking System, cannabis products, packaging and labelling and cannabis for medical purposes, and also provides additional details on the proposed regulation in these and other areas.

Health Canada intends to propose post-market amendments to the Medical Devices Regulations

By Andrew Mandlsohn

On April 10, 2018, Health Canada issued a Notice of Intent to “propose regulatory changes to strengthen the post-market surveillance and risk management of medical devices in Canada.” The intended amendments are to reflect changes made to the Food and Drugs Act (FDA) following the enactment of the Protecting Canadians from Unsafe Drugs Act (Vanessa’s Law). The proposed changes will, among other things, provide the Minister of Health with the authority to: (i) request analytical issue reports from a manufacturer when there is suspicion of a safety concern; (ii) require manufacturers to prepare annual reports and to notify Health Canada of any significant change in the safety of a medical device; (iii) compel manufacturers to conduct a reassessment and to require tests and studies; and (iv) require manufacturers to provide notification to Health Canada of any risk communications, changes to labelling, recalls, assessments, and suspensions, or revocations occurring in other countries. Health Canada intends to pre-publish the proposed regulatory amendments in 2019.

Court Decisions

Apotex not entitled to reopen trial on esomeprazole (NEXIUM) patent validity

By Lynn Ing

After the Supreme Court of Canada (SCC) held that AstraZeneca’s patent relating to esomeprazole (NEXIUM) was not invalid for inutility (see SCC strikes down “promise doctrine”) and the SCC’s dismissal of Apotex’s post-judgment motion for reconsideration and rehearing (see Update on AstraZeneca SCC), Apotex sought to raise new grounds of patent invalidity in the Federal Court, premised on “overpromising” under insufficiency, wilful misleading and overbreadth. Justice Locke dismissed Apotex’s motion (AstraZeneca v Apotex, 2018 FC 185): the validity of the patent was finally decided by the SCC; any doubt that might have remained about the SCC’s intent was resolved by the SCC’s dismissal of Apotex’s motion. Justice Locke also held that AstraZeneca was entitled to a declaration of infringement and ordered the quantification of AstraZeneca’s damages or Apotex’s profits. Apotex has appealed.

Two procedural decisions relating to HERCEPTIN under the amended PMNOC Regulations: confidentiality rules cannot be varied until action commenced; motion to dismiss may be brought prior to completion of examinations for discovery

By Abigail Smith

As previously reported, substantial amendments to the Patented Medicines (Notice of Compliance) Regulations (PMNOC Regulations) came into force on September 21, 2017. The following reports on two court decisions addressing procedure under these amendments.

On March 1, 2018, Prothonotary Aylen ruled that the Court lacked jurisdiction to consider a motion under section 5(3.7) of the PMNOC Regulations to vary confidentiality rules imposed by the person who served the notice of allegation under section 5(3.5) until an action has been commenced: Genentech, Inc. v Pfizer Canada, 2018 FC 233. Pfizer served eight Notices of Allegation on Roche with respect to Pfizer’s New Drug Submission for its TRAZIMERA product (a biosimilar of Hoffmann La-Roche’s HERCEPTIN (trastuzumab)), and simultaneously imposed confidentiality rules on those documents. Prior to the commencement of actions, Roche and Genentech (the patent owner) filed a “motion/application” to vary those rules. The Court dismissed the motion/application, finding that in the absence of proceedings, it lacked jurisdiction to consider Roche and Genentech’s “motion/application”.

On March 15, 2018, Prothonotary Aylen dismissed Pfizer’s motion to dismiss, adjourn, or delay a motion by Amgen under section 6.08 of the PMNOC Regulations seeking to summarily dismiss Roche and Genentech’s action against Amgen, which also relates to patents for Roche’s HERCEPTIN (trastuzumab):Genentech, Inc. v Amgen Canada, 2018 FC 303. The Prothonotary decided as follows:

  • Amgen’s motion, on its face, was not bereft of any prospect of success. She likened motions under section 6.08 to those under former section 6(5)(b) and motions to strike under Rule 221 of the Federal Court Rules.
  • She similarly refused to delay hearing Amgen’s motion until after the completion of examinations for discovery. The PMNOC Regulations imposed no temporal restriction on such motions and based on the schedule proposed by Amgen, Roche and Genentech would have the benefit of full documentary discovery prior to filing their motion materials.
  • Lastly, she refused to extend the 24 month statutory stay as a result of Amgen’s motion as it was not found to amount to misconduct warranting extension of the stay.

Ontario Court of Appeal dismisses summary judgment appeal in section 8 case

By Brandon Heard

As previously reported, the Ontario Superior Court of Justice dismissed Abbott and Takeda’s motion for summary judgment in an action brought by Apotex under section 8 of the PMNOC Regulations. The action relates to lansoprazole, the active ingredient in Apo-Lansoprazole and Abbott’s PREVACID. On April 5, 2018, the Ontario Court of Appeal dismissed Abbott and Takeda’s appeal: Apotex Inc. v Abbott Laboratories Limited, 2018 ONCA 332. The appellants argued that Apo-Lansoprazole could not and would not have received regulatory approval in April 2007 and Apotex was not entitled to damages. The Court of Appeal disagreed, concluding that the motions judge did not err in finding that Apo-Lansoprazole would have received approval in April 2007. This date was consistent with Apotex’s expert evidence and the timing of Health Canada’s letter indicating that Apo-Lansoprazole was approvable in the real world. While Health Canada subsequently reversed its position, that reversal could only be relevant to the quantum of Apotex’s damages and did not render the earlier letter void ab initio.

New Court Proceedings

PM(NOC) Proceedings

L-lysine-d-amphetamine (VYVANSE): Shire v Apotex

vardenafil hydrochloride (STAXYN): Bayer v Jamp

teriparatide (FORTEO): Eli Lilly v Apotex

filgrastim (NIVESTYM): Amgen v Pfizer

Other Proceedings

Kripps Pharmacy (1979) v Attorney General of Canada

S-adenosylmethionine/silybin (AVENTI Liver Complete): Nutramax v Aventix Animal 

synthetic estriol/lactobacillus acidophilus (GYNOFLOR): Acerus Pharmaceuticals v The Minister of Health; The Attorney General of Canada

Antibody testing for food sensitivity or intolerance: W Jean Dodds v Harvey Tenenbaum; Accumetrics Animal Health; Allergenics; Viaguard Animal Health

Antibody testing for food sensitivity or intolerance: W Jean Dodds v Mindy Tenenbaum; Canadian Dog Group; Allergy Test My Pet

liraglutide (VICTOZA): Novo Nordisk v The Minister of Health; Teva

urofollitropin (BRAVELLE): Ferring v The Minister of Health

For complete details about these proceedings, click here.

Selected Rankings

Canadian IP Impact Case of the Year 
AstraZeneca v Apotex (NEXIUM)
LMG Life Sciences

Read more »

Canada’s Intellectual Property Litigation Firm of the Year
Benchmark Canada

Read more  »

 

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Smart & Biggar | Attorney Advertising

Written by:

Smart & Biggar
Contact
more
less

Smart & Biggar on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
- hide

JD Supra Privacy Policy

Updated: May 25, 2018:

JD Supra is a legal publishing service that connects experts and their content with broader audiences of professionals, journalists and associations.

This Privacy Policy describes how JD Supra, LLC ("JD Supra" or "we," "us," or "our") collects, uses and shares personal data collected from visitors to our website (located at www.jdsupra.com) (our "Website") who view only publicly-available content as well as subscribers to our services (such as our email digests or author tools)(our "Services"). By using our Website and registering for one of our Services, you are agreeing to the terms of this Privacy Policy.

Please note that if you subscribe to one of our Services, you can make choices about how we collect, use and share your information through our Privacy Center under the "My Account" dashboard (available if you are logged into your JD Supra account).

Collection of Information

Registration Information. When you register with JD Supra for our Website and Services, either as an author or as a subscriber, you will be asked to provide identifying information to create your JD Supra account ("Registration Data"), such as your:

  • Email
  • First Name
  • Last Name
  • Company Name
  • Company Industry
  • Title
  • Country

Other Information: We also collect other information you may voluntarily provide. This may include content you provide for publication. We may also receive your communications with others through our Website and Services (such as contacting an author through our Website) or communications directly with us (such as through email, feedback or other forms or social media). If you are a subscribed user, we will also collect your user preferences, such as the types of articles you would like to read.

Information from third parties (such as, from your employer or LinkedIn): We may also receive information about you from third party sources. For example, your employer may provide your information to us, such as in connection with an article submitted by your employer for publication. If you choose to use LinkedIn to subscribe to our Website and Services, we also collect information related to your LinkedIn account and profile.

Your interactions with our Website and Services: As is true of most websites, we gather certain information automatically. This information includes IP addresses, browser type, Internet service provider (ISP), referring/exit pages, operating system, date/time stamp and clickstream data. We use this information to analyze trends, to administer the Website and our Services, to improve the content and performance of our Website and Services, and to track users' movements around the site. We may also link this automatically-collected data to personal information, for example, to inform authors about who has read their articles. Some of this data is collected through information sent by your web browser. We also use cookies and other tracking technologies to collect this information. To learn more about cookies and other tracking technologies that JD Supra may use on our Website and Services please see our "Cookies Guide" page.

How do we use this information?

We use the information and data we collect principally in order to provide our Website and Services. More specifically, we may use your personal information to:

  • Operate our Website and Services and publish content;
  • Distribute content to you in accordance with your preferences as well as to provide other notifications to you (for example, updates about our policies and terms);
  • Measure readership and usage of the Website and Services;
  • Communicate with you regarding your questions and requests;
  • Authenticate users and to provide for the safety and security of our Website and Services;
  • Conduct research and similar activities to improve our Website and Services; and
  • Comply with our legal and regulatory responsibilities and to enforce our rights.

How is your information shared?

  • Content and other public information (such as an author profile) is shared on our Website and Services, including via email digests and social media feeds, and is accessible to the general public.
  • If you choose to use our Website and Services to communicate directly with a company or individual, such communication may be shared accordingly.
  • Readership information is provided to publishing law firms and authors of content to give them insight into their readership and to help them to improve their content.
  • Our Website may offer you the opportunity to share information through our Website, such as through Facebook's "Like" or Twitter's "Tweet" button. We offer this functionality to help generate interest in our Website and content and to permit you to recommend content to your contacts. You should be aware that sharing through such functionality may result in information being collected by the applicable social media network and possibly being made publicly available (for example, through a search engine). Any such information collection would be subject to such third party social media network's privacy policy.
  • Your information may also be shared to parties who support our business, such as professional advisors as well as web-hosting providers, analytics providers and other information technology providers.
  • Any court, governmental authority, law enforcement agency or other third party where we believe disclosure is necessary to comply with a legal or regulatory obligation, or otherwise to protect our rights, the rights of any third party or individuals' personal safety, or to detect, prevent, or otherwise address fraud, security or safety issues.
  • To our affiliated entities and in connection with the sale, assignment or other transfer of our company or our business.

How We Protect Your Information

JD Supra takes reasonable and appropriate precautions to insure that user information is protected from loss, misuse and unauthorized access, disclosure, alteration and destruction. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. You should keep in mind that no Internet transmission is ever 100% secure or error-free. Where you use log-in credentials (usernames, passwords) on our Website, please remember that it is your responsibility to safeguard them. If you believe that your log-in credentials have been compromised, please contact us at privacy@jdsupra.com.

Children's Information

Our Website and Services are not directed at children under the age of 16 and we do not knowingly collect personal information from children under the age of 16 through our Website and/or Services. If you have reason to believe that a child under the age of 16 has provided personal information to us, please contact us, and we will endeavor to delete that information from our databases.

Links to Other Websites

Our Website and Services may contain links to other websites. The operators of such other websites may collect information about you, including through cookies or other technologies. If you are using our Website or Services and click a link to another site, you will leave our Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We are not responsible for the data collection and use practices of such other sites. This Policy applies solely to the information collected in connection with your use of our Website and Services and does not apply to any practices conducted offline or in connection with any other websites.

Information for EU and Swiss Residents

JD Supra's principal place of business is in the United States. By subscribing to our website, you expressly consent to your information being processed in the United States.

  • Our Legal Basis for Processing: Generally, we rely on our legitimate interests in order to process your personal information. For example, we rely on this legal ground if we use your personal information to manage your Registration Data and administer our relationship with you; to deliver our Website and Services; understand and improve our Website and Services; report reader analytics to our authors; to personalize your experience on our Website and Services; and where necessary to protect or defend our or another's rights or property, or to detect, prevent, or otherwise address fraud, security, safety or privacy issues. Please see Article 6(1)(f) of the E.U. General Data Protection Regulation ("GDPR") In addition, there may be other situations where other grounds for processing may exist, such as where processing is a result of legal requirements (GDPR Article 6(1)(c)) or for reasons of public interest (GDPR Article 6(1)(e)). Please see the "Your Rights" section of this Privacy Policy immediately below for more information about how you may request that we limit or refrain from processing your personal information.
  • Your Rights
    • Right of Access/Portability: You can ask to review details about the information we hold about you and how that information has been used and disclosed. Note that we may request to verify your identification before fulfilling your request. You can also request that your personal information is provided to you in a commonly used electronic format so that you can share it with other organizations.
    • Right to Correct Information: You may ask that we make corrections to any information we hold, if you believe such correction to be necessary.
    • Right to Restrict Our Processing or Erasure of Information: You also have the right in certain circumstances to ask us to restrict processing of your personal information or to erase your personal information. Where you have consented to our use of your personal information, you can withdraw your consent at any time.

You can make a request to exercise any of these rights by emailing us at privacy@jdsupra.com or by writing to us at:

Privacy Officer
JD Supra, LLC
10 Liberty Ship Way, Suite 300
Sausalito, California 94965

You can also manage your profile and subscriptions through our Privacy Center under the "My Account" dashboard.

We will make all practical efforts to respect your wishes. There may be times, however, where we are not able to fulfill your request, for example, if applicable law prohibits our compliance. Please note that JD Supra does not use "automatic decision making" or "profiling" as those terms are defined in the GDPR.

  • Timeframe for retaining your personal information: We will retain your personal information in a form that identifies you only for as long as it serves the purpose(s) for which it was initially collected as stated in this Privacy Policy, or subsequently authorized. We may continue processing your personal information for longer periods, but only for the time and to the extent such processing reasonably serves the purposes of archiving in the public interest, journalism, literature and art, scientific or historical research and statistical analysis, and subject to the protection of this Privacy Policy. For example, if you are an author, your personal information may continue to be published in connection with your article indefinitely. When we have no ongoing legitimate business need to process your personal information, we will either delete or anonymize it, or, if this is not possible (for example, because your personal information has been stored in backup archives), then we will securely store your personal information and isolate it from any further processing until deletion is possible.
  • Onward Transfer to Third Parties: As noted in the "How We Share Your Data" Section above, JD Supra may share your information with third parties. When JD Supra discloses your personal information to third parties, we have ensured that such third parties have either certified under the EU-U.S. or Swiss Privacy Shield Framework and will process all personal data received from EU member states/Switzerland in reliance on the applicable Privacy Shield Framework or that they have been subjected to strict contractual provisions in their contract with us to guarantee an adequate level of data protection for your data.

California Privacy Rights

Pursuant to Section 1798.83 of the California Civil Code, our customers who are California residents have the right to request certain information regarding our disclosure of personal information to third parties for their direct marketing purposes.

You can make a request for this information by emailing us at privacy@jdsupra.com or by writing to us at:

Privacy Officer
JD Supra, LLC
10 Liberty Ship Way, Suite 300
Sausalito, California 94965

Some browsers have incorporated a Do Not Track (DNT) feature. These features, when turned on, send a signal that you prefer that the website you are visiting not collect and use data regarding your online searching and browsing activities. As there is not yet a common understanding on how to interpret the DNT signal, we currently do not respond to DNT signals on our site.

Access/Correct/Update/Delete Personal Information

For non-EU/Swiss residents, if you would like to know what personal information we have about you, you can send an e-mail to privacy@jdsupra.com. We will be in contact with you (by mail or otherwise) to verify your identity and provide you the information you request. We will respond within 30 days to your request for access to your personal information. In some cases, we may not be able to remove your personal information, in which case we will let you know if we are unable to do so and why. If you would like to correct or update your personal information, you can manage your profile and subscriptions through our Privacy Center under the "My Account" dashboard. If you would like to delete your account or remove your information from our Website and Services, send an e-mail to privacy@jdsupra.com.

Changes in Our Privacy Policy

We reserve the right to change this Privacy Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our Privacy Policy will become effective upon posting of the revised policy on the Website. By continuing to use our Website and Services following such changes, you will be deemed to have agreed to such changes.

Contacting JD Supra

If you have any questions about this Privacy Policy, the practices of this site, your dealings with our Website or Services, or if you would like to change any of the information you have provided to us, please contact us at: privacy@jdsupra.com.

JD Supra Cookie Guide

As with many websites, JD Supra's website (located at www.jdsupra.com) (our "Website") and our services (such as our email article digests)(our "Services") use a standard technology called a "cookie" and other similar technologies (such as, pixels and web beacons), which are small data files that are transferred to your computer when you use our Website and Services. These technologies automatically identify your browser whenever you interact with our Website and Services.

How We Use Cookies and Other Tracking Technologies

We use cookies and other tracking technologies to:

  1. Improve the user experience on our Website and Services;
  2. Store the authorization token that users receive when they login to the private areas of our Website. This token is specific to a user's login session and requires a valid username and password to obtain. It is required to access the user's profile information, subscriptions, and analytics;
  3. Track anonymous site usage; and
  4. Permit connectivity with social media networks to permit content sharing.

There are different types of cookies and other technologies used our Website, notably:

  • "Session cookies" - These cookies only last as long as your online session, and disappear from your computer or device when you close your browser (like Internet Explorer, Google Chrome or Safari).
  • "Persistent cookies" - These cookies stay on your computer or device after your browser has been closed and last for a time specified in the cookie. We use persistent cookies when we need to know who you are for more than one browsing session. For example, we use them to remember your preferences for the next time you visit.
  • "Web Beacons/Pixels" - Some of our web pages and emails may also contain small electronic images known as web beacons, clear GIFs or single-pixel GIFs. These images are placed on a web page or email and typically work in conjunction with cookies to collect data. We use these images to identify our users and user behavior, such as counting the number of users who have visited a web page or acted upon one of our email digests.

JD Supra Cookies. We place our own cookies on your computer to track certain information about you while you are using our Website and Services. For example, we place a session cookie on your computer each time you visit our Website. We use these cookies to allow you to log-in to your subscriber account. In addition, through these cookies we are able to collect information about how you use the Website, including what browser you may be using, your IP address, and the URL address you came from upon visiting our Website and the URL you next visit (even if those URLs are not on our Website). We also utilize email web beacons to monitor whether our emails are being delivered and read. We also use these tools to help deliver reader analytics to our authors to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

Analytics/Performance Cookies. JD Supra also uses the following analytic tools to help us analyze the performance of our Website and Services as well as how visitors use our Website and Services:

  • HubSpot - For more information about HubSpot cookies, please visit legal.hubspot.com/privacy-policy.
  • New Relic - For more information on New Relic cookies, please visit www.newrelic.com/privacy.
  • Google Analytics - For more information on Google Analytics cookies, visit www.google.com/policies. To opt-out of being tracked by Google Analytics across all websites visit http://tools.google.com/dlpage/gaoptout. This will allow you to download and install a Google Analytics cookie-free web browser.

Facebook, Twitter and other Social Network Cookies. Our content pages allow you to share content appearing on our Website and Services to your social media accounts through the "Like," "Tweet," or similar buttons displayed on such pages. To accomplish this Service, we embed code that such third party social networks provide and that we do not control. These buttons know that you are logged in to your social network account and therefore such social networks could also know that you are viewing the JD Supra Website.

Controlling and Deleting Cookies

If you would like to change how a browser uses cookies, including blocking or deleting cookies from the JD Supra Website and Services you can do so by changing the settings in your web browser. To control cookies, most browsers allow you to either accept or reject all cookies, only accept certain types of cookies, or prompt you every time a site wishes to save a cookie. It's also easy to delete cookies that are already saved on your device by a browser.

The processes for controlling and deleting cookies vary depending on which browser you use. To find out how to do so with a particular browser, you can use your browser's "Help" function or alternatively, you can visit http://www.aboutcookies.org which explains, step-by-step, how to control and delete cookies in most browsers.

Updates to This Policy

We may update this cookie policy and our Privacy Policy from time-to-time, particularly as technology changes. You can always check this page for the latest version. We may also notify you of changes to our privacy policy by email.

Contacting JD Supra

If you have any questions about how we use cookies and other tracking technologies, please contact us at: privacy@jdsupra.com.

- hide

This website uses cookies to improve user experience, track anonymous site usage, store authorization tokens and permit sharing on social media networks. By continuing to browse this website you accept the use of cookies. Click here to read more about how we use cookies.